NATERA INC (NTRA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NTRA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NTRA | Director | 67 | ["Wilson Professor of Surgery in the field of oncology emerita at Harvard Medical School","senior fellow in healthcare policy at the Harvard Kennedy School of Government","held various professor of surgery roles at Harvard Medical School from 1999-2022","associate surgeon in the Surgical Oncology division at Brigham and Women’s Hospital and Dana-Farber Cancer Institute","chief of the Surgical Oncology division from 2008-2018","chair of the board of directors of the American Society of Clinical Oncology (ASCO) from 2020-2021","group chair and president of the Alliance for Clinical Trials in Oncology Foundation from 2011-2022","chief executive officer of Alliance Foundation Trials, LLC from 2014-2022","served on the board of directors of the American Cancer Society from 2020-2022","served on the board of Prevent Cancer from 2018-2022","served on the board of Leap Therapeutics from 2018-2022","extensive clinical experience in oncology"] | ["Nominating","Corporate Governance and Compliance"] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Bertagnolli previously joined our board of directors in November 2020 and served on our board until August 2022, when she resigned due to her appointment as Director of the National Cancer Institute (NCI). Dr. Bertagnolli rejoined our board of directors in March 2025. Dr. Bertagnolli served as Director of the NCI from October 2022 to November 2023, and as the Director of the National Institutes of Health from November 2023 to January 2025. Dr. Bertagnolli currently serves as the Wilson Professor of Surgery in the field of oncology emerita at Harvard Medical School and as a senior fellow in healthcare policy at the Harvard Kennedy School of Government. Dr. Bertagnolli held various professor of surgery roles at Harvard Medical School from 1999-2022, including professor of surgery in the field of surgical oncology. Dr. Bertagnolli was also an associate surgeon in the Surgical Oncology division at Brigham and Women s Hospital and Dana-Farber Cancer Institute; she was previously, from 2008-2018, chief of the Surgical Oncology division. Dr. Bertagnolli previously served as chair of the board of directors of the American Society of Clinical Oncology (ASCO) from 2020-2021; as group chair and president of the Alliance for Clinical Trials in Oncology Foundation from 2011-2022; and as chief executive officer of Alliance Foundation Trials, LLC from 2014-2022. In addition, Dr. Bertagnolli served on the board of directors of the American Cancer Society from 2020-2022; Prevent Cancer from 2018-2022; Leap Therapeutics, a biotechnology company, from 2018-2022, Phenomic AI, a private biotechnology company, and on numerous committees and advisory boards. Dr. Bertagnolli holds a BSE in Biochemical Engineering from Princeton University, an M.D. from the University of Utah College of Medicine, and an M.A. in the Science of Medicine from Harvard University. Our board of directors believes that Dr. Bertagnolli is qualified to serve as a director based on her career as a leading oncology researcher and her extensive clinical experience in oncology. Ms. Bertagnolli serves on our nominating, corporate governance and compliance committee.